Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 12-Month Low After Analyst Downgrade

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s stock price hit a new 52-week low during mid-day trading on Wednesday after UBS Group lowered their price target on the stock from $117.00 to $113.00. UBS Group currently has a neutral rating on the stock. Jazz Pharmaceuticals traded as low as $102.86 and last traded at $103.53, with a volume of 304466 shares trading hands. The stock had previously closed at $105.09.

Several other research firms have also issued reports on JAZZ. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Stifel Nicolaus lifted their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Truist Financial reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Finally, Needham & Company LLC decreased their price objective on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, June 20th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $188.62.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 4.20% of the stock is owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC bought a new stake in Jazz Pharmaceuticals in the third quarter worth $249,000. Mariner LLC grew its position in Jazz Pharmaceuticals by 10.4% during the 3rd quarter. Mariner LLC now owns 8,037 shares of the specialty pharmaceutical company’s stock valued at $1,040,000 after purchasing an additional 757 shares during the last quarter. Toronto Dominion Bank bought a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at about $1,813,000. AQR Capital Management LLC raised its holdings in Jazz Pharmaceuticals by 40.8% in the third quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company’s stock worth $23,184,000 after buying an additional 51,871 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 6.9% in the third quarter. Advisors Asset Management Inc. now owns 10,019 shares of the specialty pharmaceutical company’s stock worth $1,297,000 after buying an additional 649 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Down 1.5 %

The stock has a market cap of $6.53 billion, a PE ratio of 21.66, a PEG ratio of 1.64 and a beta of 0.58. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The stock’s fifty day moving average price is $108.80 and its 200 day moving average price is $116.44.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 15.35 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.